Drug intelligence / Profile preview

FHL-901

Development stage: Preclinical
Lead developer: FHL Therapeutics
Modality: Small Molecules

Overview

**FHL-901** is an undisclosed preclinical small-molecule combination being developed by Forest Hills Partners Hong Kong for neurodegenerative diseases, including Huntington's disease, Alzheimer's disease, and Parkinson's disease. Public pipeline information describes neuronal-protective activity, lysosomal-biogenesis-mediated clearance of pathogenic molecules, and attenuation of brain inflammation; however, the individual active components, direct molecular targets, formulation, and route of administration have not been publicly disclosed.

Beyond the preview

Go deeper on FHL-901.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FHL-901.

Explore the full profile